The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia
Abstract
The high prevalence of methicillin resistance among Staphylococcus aureus bacteremias leads to common use of vancomycin as empirical therapy. However, investigators have reported poor outcomes with vancomycin treatment for methicillin-susceptible Staphylococcus aureus bacteremia. We review the evidence supporting empirical combination of both vancomycin and a β-lactam agent for Staphylococcus aureus bacteremia. Vancomycin therapy for methicillin-susceptible Staphylococcus aureus bacteremia is associated with 2-3 times the risk of morbidity and mortality compared to an antistaphylococcal penicillin (oxacillin and nafcillin) or first-generation cephalosporin (cefazolin). De-escalation of empirical vancomycin to definitive β-lactam therapy still appears inferior to initial β-lactam therapy. Although there is no clinical trial supporting combination therapy, a scientific rationale for benefit exists and should be weighed against the risks (adverse events, antibiotic resistance, and cost) of additional pharmacotherapy. The empirical combination of vancomycin and a β-lactam (either nafcillin, oxacillin, or cefazolin) for staphylococcal bacteremia may improve infection-related clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The meta-analysis included small, retrospective studies, however, which limits support for initial combination therapy by some experts.”
In the citing paper
“An analysis of the literature, however, compared the use of empirical combination of vancomycin and antistaphylococcal β-lactam therapy with vancomycin alone and demonstrated the superiority of β-lactam-containing regimens over vancomycin monotherapy for bacteremic MSSA infections, including IE. 154”
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., Fridkin, S., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,582
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Lodise, T. P., McKinnon, P. S., Swiderski, L., & Rybak, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375057 · Cited by 604
Chang, F.-Y., Peacock, J. E., Musher, D. M., Triplett, P., MacDonald, B. B., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091184.93122.09 · Cited by 530
Frazee, B. W., Lynn, J., Charlebois, E. D., Lambert, L., Lowery, D., & Perdreau-Remington, F. (2005) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2004.10.011 · Cited by 494 · cited 1×
“In one study, approximately 50% of emergency department visits for skin and soft tissue infections were positive for MRSA [8].”
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq015 · Cited by 384
Chang, F.-Y., MacDonald, B. B., Peacock, J. E., Musher, D. M., Triplett, P., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091185.93122.40 · Cited by 349
Research works printed but not linked: 3
- 2011, Clinical Infectious Diseases, 531, S4
- Rudolph, 1973, JAMA, 223, 499, 10.1001/jama.1973.03220050011003 · doi:10.1001/jama.1973.03220050011003
- 1971, Postgraduate Medical Journal, 47, 64
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Woods, C. R., Bradley, J. S., Chatterjee, A., Copley, L. A., Robinson, J., Kronman, M. P., Arrieta, A., Fowler, S. L., Harrison, C., Carrillo-Marquez, M. A., et al. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab027 · Cited by 308
Leong, H. N., Kurup, A., Tan, M. Y., Kwa, A. L., Liau, K. H., & Wilcox, M. H. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s172366 · Cited by 109
Metadata
- Authors
- McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A.
- Affiliations
- University of Illinois Chicago (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-28
- Volume
- 57
- Issue
- 12
- Pages
- 1760-1765
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157481885
- Semantic Scholar
- 978015d30fdc02a4a6b93c21edf1e68c6ece1978
- Cited by
- 90
- References
- 47
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 12 · 2014: 10 · 2013: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- vancomycin, beta-lactam antibiotics, Staphylococcus aureus bacteremia, methicillin-susceptible Staphylococcus aureus, oxacillin, nafcillin, cefazolin, de-escalation, antibiotic adverse events, antibiotic costs
- MeSH terms
- Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Staphylococcal Infections, Vancomycin, Cohort Studies, Bacteremia, beta-Lactams, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia. https://app.cochat.ai/papers/10.1093/cid/cit560
- The paper
- McConeghy, K. W., Bleasdale, S. C., & Rodvold, K. A. (2013). The Empirical Combination of Vancomycin and a -Lactam for Staphylococcal Bacteremia. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cit560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.